Current pharmacotherapy options for type 2 diabetes

Abstract The goal of type 2 diabetes (T2D) therapy is to achieve outcomes that are associated with the diagnosis of the disease itself and centred at reversing the increased levels of blood glucose and glycated haemoglobin. The common approaches in T2D management are lifestyle changes such as dietary control and exercise regimens as well as pharmacotherapy interventions. This chapter outlines the chemical and pharmacological profiles of the current T2D drugs of choices. The various classes of compounds starting from the old drugs of biguanides represented by metformin to new additions in recent years are exhibited. Among the other classes of drugs detailed are the glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) analogues and receptor agonists; dipeptidyl peptidase-4 (DPP-4), sodium–glucose cotransporter-2 (SGL2) and α-glucosidase inhibitors; sulfonylureas and meglitinides; thiazolidinedione; insulin preparations, etc.

• Publication year

  2019

• Venue

  Medicinal Foods as Potential Therapies for Type-2 Diabetes and Associated Diseases

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/B978-0-08-102922-0.00005-5
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Thiazolidinediones as antidiabetic agents: A critical review.

  2018cited by this paper
• Insulin therapy for type 2 diabetes – are we there yet? The d-Nav® story

  2018cited by this paper
• Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis

  2018cited by this paper
• Efficacy of metformin on glycemic control and weight in drug-naive type 2 diabetes mellitus patients: A systematic review and meta-analysis of placebo-controlled randomized trials.

  2018cited by this paper
• AACE/ACE Consensus Statement CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2018 EXECUTIVE SUMMARY

  2018cited by this paper
• Effect of glucose-lowering therapies on heart failure

  2018cited by this paper
• Recent Advances in Synthetic α‐Glucosidase Inhibitors

  2017cited by this paper
• Current Therapies That Modify Glucagon Secretion: What Is the Therapeutic Effect of Such Modifications?

  2017cited by this paper
• Effect of Long-term Incretin-Based Therapies on Ischemic Heart Diseases in Patients with Type 2 Diabetes Mellitus: A Network Meta-analysis

  2017cited by this paper
• Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.

  2016cited by this paper
• Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control.

  2016cited by this paper
• 2. Classification and Diagnosis of Diabetes

  2016cited by this paper
• Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update.

  2016cited by this paper
• Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes

  2015cited by this paper
• Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists

  2015cited by this paper
• Prediabetes and lifestyle modification: time to prevent a preventable disease.

  2014cited by this paper
• Metformin in patients with type 2 diabetes and kidney disease: a systematic review.

  2014cited by this paper
• Comparison of Acarbose and Voglibose in Diabetes Patients Who Are Inadequately Controlled with Basal Insulin Treatment: Randomized, Parallel, Open-Label, Active-Controlled Study

  2013cited by this paper
• Cell signalling in insulin secretion: the molecular targets of ATP, cAMP and sulfonylurea

  2012cited by this paper
• The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action

  2010cited by this paper
• Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus.

  2008cited by this paper
• Review Article Peroxisome Proliferator-activated Receptor Targets for the Treatment of Metabolic Diseases

  year unknowncited by this paper

• Advances in Drug Treatments for Companion Animal Obesity

  2024cites this paper
• MOLECULAR DOCKING STUDY OF EPIGALLOCATECHIN GALLATE (EGCG) AS A THERAPY FOR TYPE 2 DIABETES MELLITUS

  2024cites this paper
• Phospholipid and n-alkane composition, anti-α-glucosidase and anti-cyclooxygenase activities of milk thistle oil

  2021cites this paper
• Plant Alkaloids with Antidiabetic Potential

  2021cites this paper
• Literature review: anti-diabetic potential of some selected edible vegetables in tropical region

  2021cites this paper
• Inhibitory potential on key enzymes relevant to type II diabetes mellitus and antioxidant properties of the various extracts and phytochemical constituents from Rumex acetosella L.

  2020cites this paper